# New Research on CBD and CBG for Fatty Liver Disease > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-cbg-fatty-liver-disease-research/ > **Published:** 2026-03-10T07:06:16-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:59:42-04:00 > **Clinical Summary:** Explore how CBD and CBG fatty liver disease research offers promising therapeutic options beyond lifestyle changes for liver health. --- ✦ New CED Clinical Relevance#72Notable Clinical InterestEmerging findings or policy developments worth monitoring closely. ResearchCBDHemp Why This MattersClinicians managing patients with nonalcoholic [fatty liver disease](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/) now have preliminary evidence that CBD and CBG could offer a therapeutic option beyond lifestyle modification alone, potentially addressing a condition affecting nearly 25% of the global population. This research is clinically significant because it identifies specific, non-intoxicating [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) that may target liver pathology without the psychoactive effects that limit patient acceptance and workplace safety. Given the lack of FDA-approved pharmacotherapies for fatty liver disease, these findings could inform future [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and treatment guidelines if efficacy is confirmed in human studies. Clinical Summary Researchers at Hebrew University of Jerusalem have identified a potential mechanism by which cannabidiol (CBD) and cannabigerol (CBG), two non-intoxicating [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/), may reduce hepatic steatosis and combat fatty liver disease. This preclinical finding is particularly relevant given the rising prevalence of non-alcoholic fatty liver disease (NAFLD) in clinical practice and the limited pharmaceutical options currently available for its treatment. The non-intoxicating profile of these cannabinoids may offer an advantage over whole cannabis products for patients concerned about psychoactive effects or drug interactions. Clinicians should note that while these results are promising, they represent early-stage research and [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) in humans are needed before these compounds can be considered for routine therapeutic use in liver disease management. For now, patients with fatty liver disease should continue to rely on established interventions including weight loss, dietary modification, and exercise, while remaining alert to future developments in cannabinoid-based therapies. Physicians managing patients with NAFLD may mention this emerging research when discussing long-term treatment prospects, but should not alter current clinical practice based on preclinical data alone. Dr. Caplan’s Take“What’s significant here is that we’re finally getting mechanistic data on how cannabinoids might address metabolic dysfunction at the hepatic level, which matters because fatty liver disease is now the most common liver pathology I see in primary care, and our conventional options are limited to lifestyle modification and weight loss that most patients struggle to achieve.” Clinical Perspective While preclinical findings suggesting cannabinoid efficacy against hepatic steatosis are intriguing, clinicians should recognize that laboratory demonstrations of mechanism do not yet establish clinical benefit or optimal dosing in human populations with fatty liver disease. The study’s in vitro and animal model results require replication and translation through rigorous clinical trials before informing practice, particularly given the heterogeneity of non-alcoholic fatty liver disease and the complexity of cannabinoid pharmacokinetics and drug interactions in patients with underlying liver dysfunction. Additionally, the regulatory landscape for [cannabis-derived therapeutics](https://cedclinic.com/cannabis-related-regulatory-documents-dea/) remains fragmented across jurisdictions, limiting standardized formulations and quality assurance that would be necessary for clinical recommendation. At present, the most evidence-supported approach to fatty liver disease management remains lifestyle modification, weight loss, and management of metabolic comorbidities; however, patients increasingly inquire about cannabinoids, warranting clinicians to stay informed on emerging 💬 Join the Conversation Have a question about how this applies to your situation?[Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers?[Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Scientists+Discover+How+Cannabis+Compounds+May+Fight+Fatty+Liver+Disease+-+NDTV+%40drcaplan&url=https%3A%2F%2Fwww.ndtv.com%2Fscience%2Fscientists-discover-how-cannabis-compounds-may-fight-fatty-liver-disease-11194303)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.ndtv.com%2Fscience%2Fscientists-discover-how-cannabis-compounds-may-fight-fatty-liver-disease-11194303)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Scientists+Discover+How+Cannabis+Compounds+May+Fight+Fatty+Liver+Disease+-+NDTV+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.ndtv.com%2Fscience%2Fscientists-discover-how-cannabis-compounds-may-fight-fatty-liver-disease-11194303)📷 Follow on Instagram[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.ndtv.com/science/scientists-discover-how-cannabis-compounds-may-fight-fatty-liver-disease-11194303](https://www.ndtv.com/science/scientists-discover-how-cannabis-compounds-may-fight-fatty-liver-disease-11194303) Further Reading Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Compounds Exhibit Potential in Combatting Fatty Liver Disease](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) Explore detailed findings on how cannabis compounds may help reduce fatty liver disease and improve liver health. [Read More](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) [CBD and CBG Promising Treatments for Fatty Liver Disease](https://cedclinic.com/cbd-cbg-fatty-liver-disease-study/) Learn about new studies highlighting the therapeutic promise of CBD and CBG for managing fatty liver disease. [Discover Insights](https://cedclinic.com/cbd-cbg-fatty-liver-disease-study/) [Cannabis Compounds Show Promise in Fighting Fatty Liver Disease](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) Scientific perspectives on how cannabis compounds may target fatty liver disease with minimal psychoactive effects. [Explore Research](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).